Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Enlivex Therapeutics Ltd
(NQ:
ENLV
)
1.460
-0.020 (-1.35%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Enlivex Therapeutics Ltd
< Previous
1
2
3
4
Next >
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
June 26, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
This Biotech Is Bringing Balance To The Body – How Homeostasis Is Critical To Fighting Everything From Sepsis To Cancer
June 16, 2023
Oren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics Ltd. (NASDAQ: ENLV) was recently a guest on Benzinga’s All-Access.
Via
Benzinga
Enlivex to Present at the 2023 Jefferies Healthcare Conference
June 06, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy
May 31, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy
May 08, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy
April 19, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Appoints Andrew Singer to its Board of Directors
April 17, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials
April 14, 2023
Via
ACCESSWIRE
Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials
April 13, 2023
This month, H.C. Wainwright & Co.
Via
Benzinga
Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors
April 12, 2023
Via
ACCESSWIRE
Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors
April 11, 2023
This month, Enlivex Therapeutics Ltd.
Via
Benzinga
Why Pioneer Natural Resources Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
April 10, 2023
Gainers PLx Pharma Inc. (NASDAQ: PLXP) jumped 149.6% to $0.2623 in pre-market trading after dropping over 13% on Thursday.
Via
Benzinga
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates
April 04, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors
April 03, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers
March 20, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Receives Clearance From Spanish Agency of Medicines and Medical Devices For Treatment of Patients with Advanced Solid Malignancies in the Ongoing Allocetra Phase I/II Clinical Trial
February 23, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS
February 15, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors
January 25, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium
January 04, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial
December 07, 2022
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that Israel, Spain and Greece have cleared amendments to the company’s Phase II trial protocol that will allow the study to enroll more patients.
Via
TheNewswire.com
A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial
December 07, 2022
By Rachael Green, Benzinga
Via
News Direct
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
December 06, 2022
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.
Via
TheNewswire.com
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
December 06, 2022
By Ernest Dela Aglanu, Benzinga
Via
News Direct
Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update
December 05, 2022
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
December 02, 2022
By Rachael Green, Benzinga
Via
News Direct
First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
December 02, 2022
On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dosed in its Phase I/II clinical trial of Allocetra. The novel off-the-shelf cell therapy is designed to help break...
Via
TheNewswire.com
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
December 01, 2022
The Israeli Ministry of Health (MOH) approved a Phase I/II trial of Enlivex Therapeutics Ltd.’s (NASDAQ: ENLV) proprietary immunotherapy drug-candidate AllocetraTM.
Via
TheNewswire.com
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
December 01, 2022
By Rachael Green, Benzinga
Via
News Direct
FDA Clears Enlivex Therapeutics' IND Application To Study Allocetra™ in Patients with Advanced Solid Malignancies
November 29, 2022
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that the U.S. Food & Drug Administration (FDA) had cleared an Investigational New Drug (IND) application to study Allocetra™ in patients with...
Via
Benzinga
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
November 28, 2022
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.